Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Authors
Jones, RVuky, J
Elliott, Tony
Mead, G
Arranz, J
Chester, J
Chowdhury, S
Dudek, A
Müller-Mattheis, V
Grimm, M
Gschwend, J
Wülfing, C
Albers, P
Li, J
Osmukhina, A
Skolnik, J
Hudes, G
Affiliation
Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.Issue Date
2013-08
Metadata
Show full item recordAbstract
AZD4877 is a potent inhibitor of the mitotic spindle kinesin, Eg5. Early-phase clinical studies in a broad range of cancers showed that AZD4877 is well tolerated. This Phase II study evaluated the efficacy, safety and pharmacokinetics (Cmax) of AZD4877 in patients with previously treated advanced urothelial cancer (ClinicalTrials.gov identifier NCT00661609).Citation
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. 2013, 31 (4):1001-7 Invest New DrugsJournal
Investigational New DrugsDOI
10.1007/s10637-013-9926-yPubMed ID
23329066Type
ArticleLanguage
enISSN
1573-0646ae974a485f413a2113503eed53cd6c53
10.1007/s10637-013-9926-y
Scopus Count
Collections
Related articles
- A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
- Authors: Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS
- Issue date: 2012 Jan
- A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
- Authors: Gerecitano JF, Stephenson JJ, Lewis NL, Osmukhina A, Li J, Wu K, You Z, Huszar D, Skolnik JM, Schwartz GK
- Issue date: 2013 Apr
- Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
- Authors: Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M
- Issue date: 2012 Jun
- A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
- Authors: Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho PT, Boerner SA, Lorusso P
- Issue date: 2011 Jun
- Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
- Authors: Pulido M, Roubaud G, Cazeau AL, Mahammedi H, Vedrine L, Joly F, Mourey L, Pfister C, Goberna A, Lortal B, Bellera C, Pourquier P, Houédé N
- Issue date: 2018 Feb 17